About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Monopar Therapeutics (MNPR): Insider Trades and Fund Holdings
In the past 12 months, Monopar Therapeutics insiders reported no open-market purchases and 5 sales worth $4.02M; 5 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 1, 2026Insider saleDirector Christopher M. Starr sold $659,386 under a 10b5-1 plan
- Oct 1, 2026Planned saleCHRISTOPHER STARR (director) filed notice to sell about $1.3 million around Oct 1, 2026
- Sep 24, 2026Insider saleCEO Chandler Robinson sold $2.6 million under a 10b5-1 plan
- Sep 24, 2026Planned saleCHANDLER ROBINSON (director, officer) filed notice to sell about $2.6 million around Sep 24, 2026
- Aug 26, 2026Insider saleDirector Kim R. Tsuchimoto sold $455,567 under a 10b5-1 plan
- Aug 26, 2026Insider saleOther Patrice Rioux sold $111 under a 10b5-1 plan
- Aug 26, 2026Planned saleKIM TSUCHIMOTO (director) filed notice to sell about $906,508 around Aug 26, 2026
- Aug 26, 2026Planned salePATRICE RIOUX (acting chief medical officer) filed notice to sell about $111 around Aug 26, 2026
- Aug 25, 2026Insider saleDirector Raymond Anderson sold $351,189 under a 10b5-1 plan
- Aug 25, 2026Planned saleRAYMOND WILLIAM ANDERSON (director) filed notice to sell about $699,786 around Aug 25, 2026
- Aug 12, 2026NewsCompany reported: Quarterly or annual results
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 5, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 5 | Christopher M. StarrDirector | ▼ SELL10b5-1 | $659K |
| Sep 28 | Chandler RobinsonCEO | ▼ SELL10b5-1 | $2.56M |
| Aug 27 | Kim R. TsuchimotoDirector | ▼ SELL10b5-1 | $456K |
| Aug 27 | Raymond AndersonDirector | ▼ SELL10b5-1 | $351K |
| Aug 27 | Patrice RiouxOther | ▼ SELL10b5-1 | $111 |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Christopher M. Starr | Director | 0 | $0 | 1 | $659K |
| Chandler Robinson | CEO | 0 | $0 | 1 | $2.56M |
| Kim R. Tsuchimoto | Director | 0 | $0 | 1 | $456K |
| Raymond Anderson | Director | 0 | $0 | 1 | $351K |
| Patrice Rioux | Other | 0 | $0 | 1 | $111 |
Buybacks and executive pay
Monopar Therapeutics spent $35 million buying back its own shares in 2025.
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $10.6M | $17.4M | n/a |
| 2024 | $1.14M | $2.36M | n/a |
| 2023 | $1.78M | −$166K | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A All 5 insider trades reported on time. How it is graded
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →